Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00001230 · ClinicalTrials.gov registry record

Host Response to Infection and Treatment in Filarial Diseases

A clinical trial of Helminthiasis and Filariasis, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Recruiting
Registry status
500
Enrollment target
1
Study location

NCT00001230: Recruiting study of Helminthiasis and Filariasis, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

NCT00001230 is a study of Helminthiasis and Filariasis that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 500 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00001230, a study of Helminthiasis and Filariasis, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

RECRUITING
Registry status
500 participants
Enrollment target
1
Study location

Study Summary

This study will evaluate and treat patients with filarial infections to explore in depth the immunology of the disease, including susceptibility to infection, disease development, and response to treatment. Filarial infections are caused by parasitic worms. The immature worm (larva) is transmitted to a person through a mosquito bite and grows in the human body to 2 to 4 inches in length. Although many of these infections do not produce symptoms, especially in the early stages of infection, others can have serious consequences, including swelling of the limbs or genitalia, allergic-lung problems, skin rash, eye inflammation that can lead to blindness, and heart disease. This protocol does not involve any experimental diagnostic procedures or treatments, and will use only procedures employed in the standard practice of medicine. Persons between 3 and 100 years of age diagnosed with or suspected of infection with Wuchereria bancrofti, Bugia malayi, Onchocerca volvulus, Loa loa, or other parasitic worms may be eligible for this study. Participants will have routine tests to determine the specific type of filarial infection. These may include special tests of the lungs, skin or heart, depending on the type of parasite suspected. Patients with skin reactions may have a "punch biopsy" to examine a small piece of affected skin. For this procedure, an area of skin is numbed with an anesthetic and a small circular area, about 1/3-inch in diameter and 1/2-inch thick, is removed using a sharp cookie cutter-type instrument. Some patients may require bronchoalveolar lavage. For this procedure, the mouth and throat are numbed with lidocaine jelly and spray and, if needed, a sedative is given for comfort. A small plastic tube is placed in a vein to give medications. A pencil-thin tube is then passed through the nose or mouth into the lung airways to examine the airways. Salt water is injected through the bronchoscope into the air passage, acting as a rinse. A sample of the fluid

Primary Outcome

Susceptibilities to filarial infection will be determined

Interventions

  • DRUG Diethylcarbamazine

Study Locations (1)

Maryland

  • National Institutes of Health Clinical Center - Bethesda

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 1991-03-15

What NCT00001230 shows while recruiting

NCT00001230 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap.

The record links to 5 conditions, with Helminthiasis appearing as the primary indexed condition, and to 1 intervention - of which Diethylcarbamazine is the first listed.

NCT00001230 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT00001230 about?

NCT00001230 is a clinical study titled "Host Response to Infection and Treatment in Filarial Diseases". This study will evaluate and treat patients with filarial infections to explore in depth the immunology of the disease, including susceptibility to infection, disease development, and response to treatment. Filarial infections are caused by parasitic worms. The immature worm (larva) is transmitted t...

What is the current status of trial NCT00001230?

This trial is currently recruiting. The enrollment target is 500 participants. The study started on 1991-03-15.

What conditions does trial NCT00001230 study?

This clinical trial studies the following conditions: Helminthiasis, Filariasis, Parasitic Infection, Mansonelliasis, Onchocerciasis.

What interventions are being tested in trial NCT00001230?

The interventions under investigation include: Diethylcarbamazine (DRUG).

Who is sponsoring clinical trial NCT00001230?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00001230 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Helminthiasis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00001529 · 500 participants

    Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

  • NCT00697411 · 500 participants

    Study of Selected X-Linked Disorders: Aicardi Syndrome

  • NCT00903110 · 500 participants

    Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).

  • NCT01035112 · 500 participants · NA

    Magnetic Resonance Imaging of Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00001230, the US trial registry maintained by the National Library of Medicine. NCT00001230 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.